Bispecific antibodies against CD3EPSILON and ROR1

US11952421B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Minh Diem Vu · Wollerau, CH
• Klaus Strein · Hemsbach, DE
• Oliver Ast · Bassersdorf, CH
• Tanja Fauti · Zürich, CH
• Anne Freimoser-Grundschober · Bellinzona, CH
• Ralf Hosse · Baar, CH
• Christian Klein · Iffeldorf, DE
• Ekkehard Moessner · Kreuzlingen, CH
• Samuel Moser · Rotkreuz, CH
• Ramona MURR · Zürich, CH
• Pablo Umana · Wollerau, CH
• Sabine Jung-Imhof · Planegg, DE
• Stefan Klostermann · Schwanau, DE
• Michael Molhoj · Munich, DE
• Joerg Thomas Regula · Munich, DE
• Wolfgang Schaefer · Sankt Augustin, DE

Key dates

• Filing date: Oct 8, 2015
• Grant date: Apr 9, 2024
• Expiry date: Oct 8, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.